The decision comes as the Voyager spacecraft face diminishing power supplies due to the gradual decay of their radioactive ...

Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...

Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...

Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...

NASA engineers are turning off two instruments to ensure that the twin spacecraft, Voyager 1 and Voyager 2, can continue ...

CROSS-SPECIES BBB-PENETRANT IV-DELIVERED AAV GENE THERAPY PROVIDES BROAD AND ROBUST CNS TAU LOWERING IN TAUOPATHY MOUSE AND ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study ...